[{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Aceclidine Hydrochloride","moa":"AchE","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Eye Drop","sponsorNew":"LENZ Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Aceclidine Hydrochloride","moa":"Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Opthalamic Solution","sponsorNew":"LENZ Therapeutics \/ RTW Investments","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ RTW Investments"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Aceclidine Hydrochloride","moa":"Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.11,"dosageForm":"Opthalamic Solution","sponsorNew":"LENZ Therapeutics \/ Ji Xing Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Ji Xing Pharmaceuticals"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"ACh receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LENZ Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Sectoral Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"Aceclidine Hydrochloride","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.080000000000000002,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Sectoral Asset Management","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Sectoral Asset Management"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"LENZ Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Merger","leadProduct":"Aceclidine Hydrochloride","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Graphite Bio \/ LENZ Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Graphite Bio \/ LENZ Therapeutics"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Aceclidine Hydrochloride","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Solution","sponsorNew":"Graphite Bio \/ Versant Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Graphite Bio \/ Versant Ventures"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Aceclidine Hydrochloride","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Solution","sponsorNew":"Graphite Bio \/ Versant Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Graphite Bio \/ Versant Ventures"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Graphite Bio","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"Aceclidine Hydrochloride","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Graphite Bio","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Graphite Bio"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Aceclidine Hydrochloride","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"LENZ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Aceclidine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"LENZ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"LENZ Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Aceclidine Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, being developed for the treatment of presbyopia.

                          Brand Name : LNZ100

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 12, 2024

                          Lead Product(s) : Aceclidine Hydrochloride

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The net proceeds will be used to fund the clinical advancement of LNZ100 (aceclidine & brimonidine tartrate), which is being evaluated in the late-stage clinical trial for the treatment of Presbyopia.

                          Brand Name : LNZ100

                          Molecule Type :

                          Upfront Cash : Undisclosed

                          July 15, 2024

                          Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Ridgeback Capital

                          Deal Size : $30.0 million

                          Deal Type : Private Placement

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : LNZ101 is a fixed dose opthalmic solution of aceclidine (mAChRs agonist) & brimonidine (ADRA2 agonist), which is being evaluated for the treatment of presbyopia.

                          Brand Name : LNZ101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 03, 2024

                          Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The net proceeds will advance LENZ’s lead programs, LNZ100 and LNZ101, preservative-free, single-use, once-daily eye drops for treating presbyopia.

                          Brand Name : LNZ101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 21, 2024

                          Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Versant Ventures

                          Deal Size : $53.5 million

                          Deal Type : Private Placement

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The collaboration will advance LENZ’s lead programs, LNZ100 and LNZ101, preservative-free eye drops containing aceclidine and aceclidine plus brimonidine for presbyopia treatment.

                          Brand Name : LNZ101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 21, 2024

                          Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Graphite Bio

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The combined will focus on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyopia.

                          Brand Name : LNZ101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 15, 2023

                          Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : LENZ Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The net proceeds will be used on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyo...

                          Brand Name : LNZ101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 15, 2023

                          Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Versant Ventures

                          Deal Size : $53.5 million

                          Deal Type : Private Placement

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The Proceeds will enable LENZ to complete the development and registration and, pending approval, launch LNZ100 (aceclidine) and LNZ101 (aceclidine and brimonidine) in the United States.

                          Brand Name : LNZ101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 07, 2023

                          Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Sectoral Asset Management

                          Deal Size : $83.5 million

                          Deal Type : Series B Financing

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Both LNZ100 (aceclidine), and LNZ101 (aceclidine + brimonidine) maintained statistical significance of three-line or greater improvement compared to vehicle for all timepoints including the last measured at 10 hours, 37% and 48% respectively.

                          Brand Name : LNZ101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 18, 2022

                          Lead Product(s) : Brimonidine Tartrate,Aceclidine Hydrochloride

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The investment by RTW promise LENZ to emerge as a global leader based on its potential best-in-class aceclidine presbyopia eye drop. Aceclidine is a small molecule acetylcholine receptor agonist that causes pupil contraction, creating pinhole effect that...

                          Brand Name : LNZ100

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 13, 2022

                          Lead Product(s) : Aceclidine Hydrochloride

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : RTW Investments

                          Deal Size : $10.0 million

                          Deal Type : Financing

                          blank